Earnings summaries and quarterly performance for THERMO FISHER SCIENTIFIC.
Executive leadership at THERMO FISHER SCIENTIFIC.
Marc N. Casper
Detailed
Chief Executive Officer
CEO
FL
Frederick Lowery
Detailed
Executive Vice President
GP
Gianluca Pettiti
Detailed
Executive Vice President
JR
James R. Meyer
Detailed
Senior Vice President and Chief Financial Officer
ML
Michel Lagarde
Detailed
Executive Vice President and Chief Operating Officer
SW
Stephen Williamson
Detailed
Senior Vice President and Chief Financial Officer
Board of directors at THERMO FISHER SCIENTIFIC.
CM
C. Martin Harris
Detailed
Director
DL
Debora L. Spar
Detailed
Director
DJ
Dion J. Weisler
Detailed
Director
JC
James C. Mullen
Detailed
Director
JM
Jennifer M. Johnson
Detailed
Director
KS
Karen S. Lynch
Detailed
Director
NJ
Nelson J. Chai
Detailed
Director
RA
R. Alexandra Keith
Detailed
Director
RR
Ruby R. Chandy
Detailed
Director
SM
Scott M. Sperling
Detailed
Lead Independent Director
TJ
Tyler Jacks
Detailed
Director
Research analysts who have asked questions during THERMO FISHER SCIENTIFIC earnings calls.
Jack Meehan
Nephron Research LLC
8 questions for TMO
Also covers: A, AVTR, BIO +17 more
Michael Ryskin
Bank of America Merrill Lynch
7 questions for TMO
Also covers: A, ALGN, AVTR +28 more
Tycho Peterson
Jefferies
6 questions for TMO
Also covers: A, AVTR, BIO +22 more
Dan Arias
Stifel Financial Corp.
4 questions for TMO
Also covers: A, GH, ILMN +9 more
DB
Dan Brennan
UBS
3 questions for TMO
Also covers: A, DHR, MDXH +8 more
Daniel Brennan
TD Cowen
3 questions for TMO
Also covers: A, ADPT, AVTR +24 more
Douglas Schenkel
Wolfe Research, LLC
3 questions for TMO
Also covers: A, AVTR, BRKR +21 more
RV
Rachel Vatnsdal Olson
JPMorgan
3 questions for TMO
Also covers: A, ADPT, AKYA +14 more
Andrew Cooper
Raymond James
2 questions for TMO
Also covers: AZTA, CDNA, CTKB +12 more
CW
Casey Woodring
JPMorgan Chase & Co.
2 questions for TMO
Also covers: A, BLLN, CRL +11 more
MS
Matthew Sykes
Goldman Sachs Group Inc.
2 questions for TMO
Also covers: A, ADPT, AVTR +21 more
ML
Matt Larew
William Blair & Co.
2 questions for TMO
Also covers: AMED, MRVI, MXCT +6 more
Patrick Donnelly
Citi
2 questions for TMO
Also covers: A, AVTR, BIO +22 more
Daniel Anthony Arias
Stifel
1 question for TMO
Michael Leonidovich Ryskin
Bank of America
1 question for TMO
PS
Puneet Souda
Leerink Partners
1 question for TMO
Also covers: A, ABCL, BRKR +20 more
Rachel Vatnsdal
JPMorgan Chase & Co.
1 question for TMO
Also covers: A, AKYA, AVTR +11 more
Recent press releases and 8-K filings for TMO.
Thermo Fisher shares fall on 2026 profit outlook
TMO
Earnings
Guidance Update
CFO Change
- Thermo Fisher reported Q4 2025 revenue of $12.21 billion (up 7%) and adjusted EPS of $6.57 (up 8%), with full-year revenue of $44.56 billion and adjusted EPS of $22.87.
- 2026 guidance calls for $46.3–$47.2 billion in revenue and adjusted EPS implying about 6%–8% growth, but the profit outlook missed Street expectations and shares fell as much as roughly 4% intraday.
- Management noted robust pharmaceutical demand but flagged softer near-term growth due to cuts and timing in U.S. academic and government research funding; analysts labeled the 1%–2% Q1 organic growth forecast as “soft”.
- CFO Stephen Williamson will retire in March, succeeded by Jim Meyer, and investors are watching the timing of the $9 billion Clario acquisition closing.
5 days ago
Thermo Fisher reports Q4 2025 results and 2026 guidance
TMO
Earnings
Guidance Update
M&A
- Thermo Fisher delivered Q4 revenue of $12.21 B (+7% Y/Y) and adjusted EPS of $6.57 (+8%), and FY 2025 revenue of $44.56 B (+4%) with adjusted EPS of $22.87 (+5%)
- 2026 guidance: revenue $46.3 B–$47.2 B (+4–6% Y/Y; 3–4% organic) and adjusted EPS of $24.22–$24.80 (+6–8%)
- Announced agreement to acquire Clario (2025 revenue ~$1.25 B), expected to close mid-2026 and be accretive $0.45 to EPS in the first 12 months
- 2025 capital deployment: $16.5 B deployed, including $13 B on M&A and $3.6 B returned to shareholders via buybacks and dividends
- Launched high-impact products in 2025, including Orbitrap Astral Zoom mass spectrometer, Krios 5 Cryo-TEM, EXENT System, and new Oncomine Dx companion diagnostic approvals
5 days ago
Thermo Fisher reports Q4 2025 results and 2026 guidance
TMO
Earnings
Guidance Update
M&A
- Q4 2025 revenue grew 7% year-over-year to $12.21 billion, with adjusted operating income up 6% to $2.88 billion and adjusted EPS rising 8% to $6.57.
- Full-year 2025 revenue increased 4% to $44.56 billion, adjusted operating income rose 4% to $10.11 billion, and adjusted EPS grew 5% to $22.87.
- 2026 guidance calls for $46.3–47.2 billion in revenue and $24.22–24.80 in adjusted EPS (6–8% growth), based on 3–4% organic revenue growth and 50 bps of margin expansion.
- Capital deployment in 2025 totaled $16.5 billion, including $13 billion for M&A (Solventum filtration, Sanofi sterile fill, Clario) and $3.6 billion returned to shareholders via buybacks and dividends.
- Segment performance in Q4: Life Science Solutions organic +4% (margin 35.5%), Analytical Instruments flat (margin 26.3%), Specialty Diagnostics organic +3% (margin 26.6%), and Lab Products & Biopharma Services organic +5% (margin 14.5%).
5 days ago
Thermo Fisher announces Q4 2025 results
TMO
Earnings
Guidance Update
M&A
- Q4 revenue grew 7% to $12.21 B, with adjusted operating income up 6% to $2.88 B, adjusted operating margin of 23.6%, and adjusted EPS rising 8% to $6.57.
- FY2025 revenue increased 4% to $44.56 B, adjusted operating income grew 4% to $10.11 B, adjusted operating margin was 22.7%, and adjusted EPS was $22.87 (up 5%).
- 2026 guidance: revenue of $46.3 B–$47.2 B (4–6% growth; ~3–4% organic) and adjusted EPS of $24.22–$24.80 (6–8% growth).
- Capital deployment in 2025 included $16.5 B deployed (approx. $13 B M&A; $3.6 B buybacks/dividends), and a definitive agreement to acquire Clario for ~$9 B expected to close mid-2026.
5 days ago
Thermo Fisher Scientific reports Q4 and full-year 2025 results
TMO
Earnings
M&A
Share Buyback
- Thermo Fisher recorded Q4 revenue of $12.21 B, up 7%, with GAAP diluted EPS of $5.21 (+9%) and adjusted EPS of $6.57 (+8%).
- For full-year 2025, revenue was $44.56 B (+4%), with GAAP EPS of $17.74 (+7%) and adjusted EPS of $22.87 (+5%).
- Deployed $16.5 B in capital (including $13 B on M&A) and returned $3.6 B to shareholders via share buybacks and dividends; closed key acquisitions and agreed to acquire Clario in Q4.
- Launched several high-impact products (e.g., Orbitrap Astral Zoom, Krios 5 Cryo-TEM), obtained FDA and 510(k) clearances for diagnostic platforms, and entered a strategic AI collaboration with OpenAI.
6 days ago
Thermo Fisher reports Q4 and FY2025 results
TMO
Earnings
M&A
Share Buyback
- Q4 revenue rose 7% to $12.21 B; GAAP EPS increased 9% to $5.21, and adjusted EPS grew 8% to $6.57.
- Full-year revenue climbed 4% to $44.56 B; GAAP EPS up 7% to $17.74, and adjusted EPS up 5% to $22.87.
- Deployed $16.5 B of capital in 2025, including $13 B on M&A and $3.6 B returned to shareholders via buybacks and dividends.
- Acquired Solventum’s Filtration & Separation business and Sanofi’s Ridgefield site, and agreed to buy Clario to bolster clinical trial data solutions.
6 days ago
Thermo Fisher details 2025 performance and 2026 outlook
TMO
Guidance Update
M&A
Share Buyback
- Thermo Fisher delivered $44 billion in revenue in 2025, supported by >120,000 colleagues and $1.4 billion in R&D investment.
- Operational excellence driven by the PPI Business System, including $300 million of cost actions and tariff adjustments to bolster resilience.
- Executed strategic capital deployment: closed the $4 billion Solventum Purification & Filtration acquisition and Sanofi Steriles site, announced the $9 billion Clario deal, and returned capital with $3 billion in share repurchases and $600 million in dividends.
- Outlook for 2026 includes improving demand trends with organic revenue growth progression and strong adjusted EPS growth.
Jan 13, 2026, 4:15 PM
Thermo Fisher reviews 2025 performance and sets 2026 outlook
TMO
Guidance Update
M&A
- Delivered $44 billion in revenue, employs 120,000 staff and invests $1 billion annually in R&D in 2025.
- Achieved mid-single-digit organic growth in pharma & biotech (first nine months of 2025) and surpassed an incremental $300 million cost-reduction target.
- Deployed capital through the acquisition of Solventum’s purification & filtration business (approx. $750 million revenue run rate) and a Sanofi fill-finish site, and announced the $9 billion Clario acquisition.
- Forecasts 3 %–6 % organic top-line growth for 2026, with a long-term target of returning to 7 %+ growth and 50–70 bps of annual margin expansion.
- Serves four end markets—56 % of 2025 revenue from pharma & biotech—within a $270 billion addressable market and holds ~20 % market share.
Jan 13, 2026, 4:15 PM
Thermo Fisher outlines 2025 results and 2026 outlook at JP Morgan Healthcare Conference
TMO
Guidance Update
M&A
- In 2025, Thermo Fisher achieved $44 billion in revenue, launched key products (Orbitrap Astral mass spectrometer, next-generation cryo-EM, scalable single-use bioreactors) and returned $3.6 billion to shareholders via buybacks and dividends
- Expanded portfolio through acquisitions: Solventum filtration platform (
$750 million revenue run-rate), Sanofi’s Ridgefield sterile fill-finish site and announced Clario deal ($1.25 billion revenue; $0.45 EPS accretion in year one) - Financial outlook targets 3%–6% organic revenue growth in 2026–27 with 50–70 bp annual margin expansion, transitioning to >7% organic growth post-2028; strategic execution powered by the PPI system and AI partnerships (OpenAI, NVIDIA)
- Advanced corporate social responsibility: >56% of global electricity from renewables (target 80% by 2030), 33 zero-waste sites and ongoing investments in education and health equity initiatives
Jan 13, 2026, 4:15 PM
Thermo Fisher outlines 2025 performance and 2026 strategy at JPMorgan Healthcare Conference
TMO
Product Launch
M&A
Share Buyback
- Thermo Fisher reported $44 billion in 2025 revenue and has delivered an average 10 % annual top-line growth over the past decade.
- The company launched key innovations in mass spectrometry (Orbitrap Astral), cryo-electron microscopy, scalable bioreactors, and diagnostics to support market share gains.
- Thermo Fisher completed the Solventum filtration acquisition and Sanofi Ridgefield site purchase, announced the $9 billion Clario deal, and returned $3.6 billion via share repurchases and dividends in 2025.
- For 2026, management will prioritize trusted partnerships, further product innovation, operational excellence through PPI and AI, active capital deployment, and advancing CSR initiatives.
Jan 13, 2026, 4:15 PM
Quarterly earnings call transcripts for THERMO FISHER SCIENTIFIC.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more